Abstract
In addition to advancing the development of gene-editing therapeutics, CRISPR/Cas9 is transforming how functional genetic studies are carried out in the lab. By increasing the ease with which genetic information can be inserted, deleted, or edited in cell and organism models, it facilitates genotype–phenotype analysis. Moreover, CRISPR/Cas9 has revolutionized the speed at which new genes underlying a particular phenotype can be identified through its application in genomic screens. Arrayed high-throughput and pooled lentiviral-based CRISPR/Cas9 screens have now been used in a wide variety of contexts, including the identification of essential genes, genes involved in cancer metastasis and tumor growth, and even genes involved in viral response. This technology has also been successfully used to identify drug targets and drug resistance mechanisms. Here, we provide a detailed protocol for performing a genome-wide pooled lentiviral CRISPR/Cas9 knockout screen to identify genetic modulators of a small-molecule drug. While we exemplify how to identify genes involved in resistance to a cytotoxic histone deacetylase inhibitor, Trichostatin A (TSA), the workflow we present can easily be adapted to different types of selections and other types of exogenous ligands or drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Horvath P, Barrangou R (2010) CRISPR/Cas, the immune system of bacteria and archaea. Science 327:167–170
Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823
Jiang F, Zhou K, Ma L et al (2015) STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition. Science 348:1477–1481
Jiang F, Doudna JA (2017) CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys 46:505–529
Grajcarek J, Monlong J, Nishinaka-Arai Y et al (2019) Genome-wide microhomologies enable precise template-free editing of biologically relevant deletion mutations. Nat Commun 10:4856
Ablain J, Zon LI (2016) Tissue-specific gene targeting using CRISPR/Cas9. Methods Cell Biol 135:189–202
Jamal M, Khan FA, Da L et al (2016) Keeping CRISPR/Cas on-target. Curr Issues Mol Biol 20:1–12
Komor AC, Badran AH, Liu DR (2018) Editing the genome without double-stranded DNA breaks. ACS Chem Biol 13:383–388
Anzalone AV, Randolph PB, Davis JR et al (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576:149–157
Hirakawa MP, Krishnakumar R, Timlin JA et al (2020) Gene editing and CRISPR in the clinic: current and future perspectives. Biosci Rep:40
Cromwell CR, Jovel J, Hubbard BP (2021) Methods for measuring CRISPR/Cas9 DNA cleavage in cells. Methods Mol Biol 2162:197–213
Cromwell CR, Hubbard BP (2021) In vitro assays for comparing the specificity of first- and next-generation CRISPR/Cas9 systems. Methods Mol Biol 2162:215–232
Maggio I, Zittersteijn HA, Wang Q et al (2020) Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components. Gene Ther 27:209–225
Cromwell CR, Sung K, Park J et al (2018) Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity. Nat Commun 9:1448
Shalem O, Sanjana NE, Hartenian E et al (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84–87
Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783–784
Sanson KR, Hanna RE, Hegde M et al (2018) Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun 9:5416
Gilbert LA, Horlbeck MA, Adamson B et al (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159:647–661
Konermann S, Brigham MD, Trevino AE et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583–588
Cross BC, Lawo S, Archer CR et al (2016) Increasing the performance of pooled CRISPR-Cas9 drop-out screening. Sci Rep 6:31782
Chen S, Sanjana NE, Zheng K et al (2015) Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160:1246–1260
Li B, Clohisey SM, Chia BS et al (2020) Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection. Nat Commun 11:164
Yang J, Rajan SS, Friedrich MJ et al (2019) Genome-scale CRISPRa screen identifies novel factors for cellular reprogramming. Stem Cell Rep 12:757–771
Shi J, Wang E, Milazzo JP et al (2015) Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 33:661–667
Reczek CR, Birsoy K, Kong H et al (2017) A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nat Chem Biol 13:1274–1279
Fang P, De Souza C, Minn K et al (2019) Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Commun Biol 2:335
Zhang R, Miner JJ, Gorman MJ et al (2016) A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature 535:164–168
Ruiz S, Mayor-Ruiz C, Lafarga V et al (2016) A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors. Mol Cell 62:307–313
Kurata M, Rathe SK, Bailey NJ et al (2016) Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci Rep 6:36199
Han K, Jeng EE, Hess GT et al (2017) Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol 35:463–474
Wang C, Jin H, Gao D et al (2018) Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol 69:1057–1065
Shen Z, Liao X, Shao Z et al (2019) Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability. BMC Cancer 19:262
Kerek EM, Yoon KH, Luo SY et al (2020) A conserved acetylation switch enables pharmacological control of tubby-like protein stability. J Biol Chem 296:100073
Doench JG, Fusi N, Sullender M et al (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184–191
Joung J, Konermann S, Gootenberg JS et al (2017) Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc 12:828–863
Malina A, Katigbak A, Cencic R et al (2014) Adapting CRISPR/Cas9 for functional genomics screens. Methods Enzymol 546:193–213
Acknowledgments
This work was supported by NSERC Discovery/Discovery Accelerator Supplement (RGPIN-2016-0638) and CIHR (PS-408552) grants to BPH.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kerek, E.M., Cromwell, C.R., Hubbard, B.P. (2021). Identification of Drug Resistance Genes Using a Pooled Lentiviral CRISPR/Cas9 Screening Approach. In: Vizeacoumar, F.J., Freywald, A. (eds) Mapping Genetic Interactions. Methods in Molecular Biology, vol 2381. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1740-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1740-3_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1739-7
Online ISBN: 978-1-0716-1740-3
eBook Packages: Springer Protocols